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Abstract
The hypocretin (orexin) system is involved in sleep/wake regulation, and antagonists of both hypocretin receptor type 1
(HCRTR1) and/or HCRTR2 are considered to be potential hypnotic medications. It is currently unclear whether blockade of
either or both receptors is more effective for promoting sleep with minimal side effects. Accordingly, we compared the
properties of selective HCRTR1 (SB-408124 and SB-334867) and HCRTR2 (EMPA) antagonists with that of the dual HCRTR1/
R2 antagonist almorexant in the rat. All 4 antagonists bound to their respective receptors with high affinity and selectivity
in vitro. Since in vivo pharmacokinetic experiments revealed poor brain penetration for SB-408124, SB-334867 was selected
for subsequent in vivo studies. When injected in the mid-active phase, SB-334867 produced small increases in rapid-eye-
movement (REM) and non-REM (NR) sleep. EMPA produced a significant increase in NR only at the highest dose studied. In
contrast, almorexant decreased NR latency and increased both NR and REM proportionally throughout the subsequent 6 h
without rebound wakefulness. The increased NR was due to a greater number of NR bouts; NR bout duration was
unchanged. At the highest dose tested (100 mg/kg), almorexant fragmented sleep architecture by increasing the number of
waking and REM bouts. No evidence of cataplexy was observed. HCRTR1 occupancy by almorexant declined 4–6 h post-
administration while HCRTR2 occupancy was still elevated after 12 h, revealing a complex relationship between occupancy
of HCRT receptors and sleep promotion. We conclude that dual HCRTR1/R2 blockade is more effective in promoting sleep
than blockade of either HCRTR alone. In contrast to GABA receptor agonists which induce sleep by generalized inhibition,
HCRTR antagonists seem to facilitate sleep by reducing waking ‘‘drive’’.
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Introduction
Determination of the functions of neurotransmitters, neuro-
modulators and their receptors has classically been aided by use of
small molecule receptor-specific antagonists. In recent years,
forward and reverse genetics have provided insights into the
functions of neurotransmitter/neuromodulatory systems before
receptor-specific antagonists were developed. Such was the case
for hypocretin (orexin), whose cell bodies in the perifornical and
lateral hypothalamus synthesize a pair of neuropeptides alterna-
tively called hypocretin-1 (HCRT1) or orexin-A and hypocretin-2
(HCRT2) or orexin-B [1,2]. Identification of a mutation in the
gene encoding HCRT receptor 2 (HCRTR2 or OX2R) as the
cause of canine narcolepsy [3] and demonstration that HCRT
ligand-deficient mice exhibited periods of behavioral arrest that
resembled both human and canine narcolepsy [4] implicated the
HCRT system in sleep/wake control well before the first small
molecule HCRT receptor antagonists [5,6,7] were described. An
extensive literature has since led to the conclusion that the HCRT
system is wake-promoting [8,9,10,11] and involved in energy
homeostasis [12,13]. Other studies have suggested roles for the
HCRT system in neuroendocrine, cardiovascular, water balance,
and gastrointestinal control [14], nociception and hyperalgesia
[15,16,17], stress and stress-induced analgesia [18,19], reward and
addiction [20,21,22,23], and panic anxiety [24].
It is currently unclear whether targeting the HCRTR2 alone or
both HCRT receptors is the best strategy for the development
of sleep-promoting compounds. Several dual HCRTR1/R2
antagonists show significant sleep-promoting properties
[25,26,27,28,29,30,31,32]. However, some reports indicate that
HCRTR2 blockade alone was sufficient to produce the hypnotic
actions of HCRTR antagonism [32,33]. One study compared the
efficacy of the selective HCRTR1 antagonist SB-408124 [34], the
selective HCRTR2 antagonist JNJ-10397049 [35], and the dual
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antagonism attenuates the hypnotic actions of HCRTR2 blockade
[32]. While data on the affinity and selectivity of these compounds
have been published, the absence of information on their
pharmacokinetic properties is problematic for interpretation of
their in vivo effects.
In the present study, we characterize the hypnotic activity of
HCRTR antagonists in rats to determine whether selective or dual
HCRTR antagonists are more effective for promoting sleep. To
ensure a meaningful in vivo comparison, we determined the
pharmacological and pharmacokinetic profiles in rats of two
selective HCRTR1 antagonists, SB-408124 and SB-334867 [36],
the selective HCRTR2 antagonist EMPA [37], and the dual
HCRTR1/R2 antagonist almorexant. After showing that SB-
408124 displays insufficient brain penetration, we used SB-334867
as the HCRTR1 antagonist for all in vivo experiments. Lastly, we
determined the time course of HCRTR occupancy by almorexant
and correlated this with hypnotic efficacy.
Materials and Methods
Drugs
Almorexant (ACT-078573, (2R)-2-[(1S)-6,7-Dimethoxy-1-[2-(4-
trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-
N-methyl-2-phenyl-acetamide) [27], EMPA N-(Ethyl-2-[(6-me-
thoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-yl-
methyl-acetamide) [37], SB-674042 (1-(5-(2-fluoro-phenyl)-2-
methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-yl-
methyl)-pyrrolidin-1-yl)-methanone) [34], and Cp-5 ((S)-1-(6,7-
Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3,3-dimethyl-2-
[(pyridin-4-ylmethyl)-amino]-butan-1-one) [7] were synthesized at
F. Hoffmann-La Roche Ltd. (Basel, Switzerland) or SRI Interna-
tional (Menlo Park, CA USA) according to the patent literature
[38]. SB-334867 (1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyri-
din-4-yl-urea hydrochloride), zolpidem (N,N,6-Trimehtyl-2-
(methylphenyl)-imidazol[1,2-a]pyridine-3-acetamide) and SB-
408124 (1-(6,8-difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethyla-
mino-phenyl)-urea) were purchased from Tocris Bioscience
(Ellisville, MO). Chemical structures are provided in Figure S1.
[
3H]almorexant (specific activity: 42.7 Ci/mmol), [
3H]SB-674042
(specific activity: 24.4 Ci/mmol) and [
3H]EMPA (specific activity:
94.3 Ci/mmol) were synthesized at Roche.
Animals
Animal experiments performed at F. Hoffmann-La Roche were
conducted in strict adherence to the Swiss federal regulations on
animal protection and to the rules of the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC), and with the explicit approval of the
local Cantonal Veterinary Office/Authority Basel City. Animal
experiments performed at SRI International were approved by
SRI’s Institutional Animal Care and Use Committee and were in
accordance with U.S. National Institute of Health guidelines. Male
Wistar rats (240620 g) used for spontaneous locomotion studies
and pharmacokinetic studies at F. Hoffmann-La Roche were
obtained from RCC Ltd. (Fullinsdorf, Switzerland). Male
Sprague-Dawley rats (300625 g) used for receptor occupancy
studies at F. Hoffmann-La Roche were from Iffa Credo (Lyon,
France). Animals were housed in separate rooms under a 12 h
light/12 h dark cycle (light onset: 06:00, except where noted
below; Zeitgeber time 0, ZT0) at 2262uC, with ad libitum access to
food and water. Male Sprague-Dawley rats (300625 g) used for
sleep studies at SRI were from Charles River (Wilmington, MA)
and were housed in a temperature-controlled recording room
under a 12 h light/12 h dark cycle (lights on at 05:00) with food
and water available ad libitum. Room temperature (2462uC),
humidity (50620% relative humidity), and lighting conditions
were monitored continuously via computer. Animals were
inspected daily in accordance with AAALAC and SRI guidelines.
Pharmacological Studies
[
3H]almorexant binding to rat HCRTR1 and
HCRTR2. The rat cDNAs encoding HCRTR1 (Accession No.
P56718) and HCRTR2 (Accession No. P56719) were subcloned
into pCI-Neo expression vectors (Promega, Madison, WI) and
used to transfect HEK293 cells (acquired commercially from
ATCC-LGC, Molsheim, France) as previously described [37].
Membrane preparations, saturation and inhibition experiments,
and determination of the association and dissociation kinetic
parameters of [
3H]almorexant to rHCRTR2-HEK293 cell
membranes were performed at F. Hoffmann-La Roche as
previously described [37] and reported in the Materials and
Methods S1.
Pharmacokinetic Studies
Pharmacokinetic analyses were performed at F. Hoffmann-La
Roche as described in supporting Maqterials and Methods S1.
SB-334867 selectivity screen. SB-334867 was evaluated in
a selectivity screen performed at CEREP (Paris, France). The
screen consisted of binding assays on a panel of 79 target
receptors. The specific binding (SB) of a radioligand to each target
receptor was defined as the difference between the total binding
and the nonspecific binding determined in the presence of a cold
competitor in excess. The results are expressed as a percent of
control SB obtained in the presence of SB-334867 used at 10 mM.
Details on the CEREP screen are available from www.cerep.fr.
Effect of Almorexant and SB-334867 on Spontaneous
Locomotor Activity in Rats
Locomotor activity (LMA) was evaluated at F. Hoffmann-La
Roche as described previously [39]. Male Wistar rats were placed
for 2 weeks in a 12 h light/12 h dark cycle with light onset at
22:00 (ZT0). Three h after the onset of the dark period (i.e.,
ZT15), rats were injected ip with either vehicle or HCRT receptor
antagonist (almorexant or SB-334867 at 3, 10, 30 mg/kg in NaCl
0.9%, 0.3% Tween-80) (n=8 per group), and returned to the
recording chambers. Spontaneous LMA was recorded for a period
of 30 min. At the end of the experiment, the brain and plasma
were collected for determination of the drug exposure and brain/
plasma concentration ratio.
Electroencephalogram, Core Body Temperature and
Locomotor Activity Studies
Surgical procedures and recordings. All rodent electro-
encephalograph (EEG) studies were performed at SRI Interna-
tional. Three groups of eight male Sprague-Dawley rats
(300625 g; Charles River, Wilmington, MA) were implanted
with chronic recording devices (F40-EET, Data Sciences Inc., St
Paul, MN) for continuous recordings of EEG, electromyograph
(EMG), core body temperature (Tcore), and LMA via telemetry as
previously described [40]. Data recording and scoring were
performed as previously reported [40] (see also Supplemental
Material and Methods). The EEG and EMG data were scored in
10 sec epochs for waking (W), rapid eye movement sleep (REM),
and non-REM sleep (NR). Tcore and LMA (counts per minute)
were analyzed as hourly means. Data from the EEG studies are
Hypocretin Receptor Antagonism and Sleep Promotion
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the hour between time points ZT0 and ZT1.
Experimental design. For each of the three separate studies,
a repeated measures counter-balanced design was employed in
which each rat received five separate dosings. The dosing
conditions for study 1 included SB-334867 at three concentrations
(3, 10 and 30 mg/kg), zolpidem (ZOL, 7.5 mg/kg) and a vehicle
control (saline 95%/ethanol 5%). The dosing conditions for study
2 included EMPA at three concentrations (10, 30 and100 mg/kg),
ZOL (10 mg/kg) and a vehicle control (HPMC). The dosing
conditions for study 3 included almorexant at three concentrations
(10, 30 and 100 mg/kg), ZOL (10 mg/kg) and a vehicle control
(HPMC). All dosings were administered ip in a volume of 2 ml/kg.
A minimum of 3 d elapsed between doses. Dosing occurred during
the middle of the rats’ normal active period at the start of ZT19
and was typically completed within 10 min. Animals were
continuously recorded for 6 h prior to dosing and for 18 h
following dosing.
Determination of HCRTR1 and HCRTR2 occupancy by
almorexant. This study was performed at F. Hoffmann-La
Roche. Sixty-five male Sprague-Dawley rats, housed 5 per cage
(light onset: 12:00), were injected intraperitoneally (ip) with either
vehicle (1.25% hydroxypropyl methylcellulose (HPMC), 0.1%
docusate sodium) or almorexant (30 mg/kg in 1.25% HPMC,
0.1% docusate sodium) at the mid-dark phase (ZT18; i.e., 6 h after
lights-off), and returned to their home cage. Groups (n=5 per
group) of vehicle- or almorexant-treated animals were then
sacrificed by decapitation 0.5, 2, 4, 8 or 12 h after the injection.
An extra group of non-injected rats (n=5) was also sampled at
ZT18. Plasma was collected and stored at 280uC until assayed.
Brains were rapidly dissected, frozen on dry ice, and stored at
280uC. Series of coronal brain sections (14 mm) were cut in a
cryostat through the posterior hypothalamus (tuberomammillary
nucleus level: 3.8 to 4.2 mm posterior to bregma) and the brain
stem (dorsal raphe nucleus level: 7.3 to 8 mm posterior to bregma;
locus coeruleus level: 29.3 to 210 mm posterior to bregma),
thaw-mounted (6 sections per slide) and stored at 220uC. After
sectioning, the remaining pieces of brain were kept at 280uC for
later determination of almorexant brain concentration. The brain
and plasma concentrations of almorexant were determined by
quantitative liquid chromatography/mass spectrometry/mass
spectrometry (LC/MS/MS).
Receptor occupancy (RO) was determined as published
previously [41]. For each Hcrt receptor subtype, two series of
slides were thawed and incubated at room temperature with the
relevant radioligand in assay buffer for 15 min (HCRTR1) or 1 h
(HCRTR2). For HCRTR1, assay buffer (2 mM CaCl2,5m M
MgCl2, 25 mM HEPES, pH 7.4, 100 mL per section) contained
either 5 nM [
3H]SB-674042 (for determination of total binding,
TB) or 5 nM [
3H]SB-674042 plus 10 mM SB-408124 (for
determination of non-specific binding, NSB). For HCRTR2,
assay buffer (1 mM CaCl2, 5 mM MgCl2, 25 mM HEPES,
pH 7.4, 120 mL per section) contained either 1 nM [
3H]EMPA
(for determination of TB) or 1 nM [
3H]EMPA plus 10 mM Cp-5
(for determination of NSB). The liquid was drained, the brain
sections were rinsed with ice-cold assay buffer (2 brief washes
followed by 362 min soaking) and distilled water (3 brief dips) and
air dried at 4uC for 12 h. The slides were exposed together with
[
3H] microscales against tritium-sensitive imaging plates (BAS-
TR2025) for 5 days. The plates were scanned with a high
resolution phosphor imager device (Fujifilm BAS-5000) and
calibrated measurements of radioactivity (fmol/mg protein) were
made. All analyses were performed blind to treatment.
For each selected region, the mean signal density (TB) was
measured and averaged from three consecutive sections from the
same slide. The specific binding (SB) signal was then determined for
eachanimal bysubtracting the NSB signal fromthe TB signal.NSB
was measured from adjacent brains sections incubated with the
radiotracer and an excess of cold competitor. The SB signal was
averaged for each experimental group and the percent RO was
calculated at each time-point according to the equation RO=(1-
(SBalmorexant/SBvehicle))6100,whereSBalmorexantistheaverageSBfor
theanimalgroupinjectedwithalmorexantandSBvehicleistheaverage
SB for the animal group injected withvehicle.
Statistical Analyses
Results are shown as mean6SEM. LMA and RO data were
analyzed with one-way ANOVA followed by Dunnett’s analysis.
EEG data were analyzed with repeated measures (rm)-ANOVA,
followed by paired two-tailed t-tests. REM:NR ratios, sleep
latencies (NR and REM) and cumulative data were analyzed with
one-way rm-ANOVA and all other data with two-way rm-
ANOVA. Light period and dark period data were analyzed
separately as well as pre- and post-drug administration data.
Statistical significance was set at P,0.05.
Results
Pharmacological Studies
Binding characteristics of [
3H]almorexant to rHCRTR1-
and rHCRTR2-expressing cell membranes. To characterize
the in vitro binding of [
3H]almorexant to rat HCRT receptors,
saturation binding analyses were performed at binding equilibrium
on membranes isolated from HEK293 cells transiently transfected
with rHCRTR1 and rHCRTR2. As shown in Fig. 1A and B,
[
3H]almorexant bound with high affinity to a single saturable site
on recombinant rHCRTR1 (Kd of 3.460.3 nM and Bmax of
27.260.7 pmol/mg prot, at 23uC) and rHCRTR2 (Kd of
0.560.0 nM and Bmax of 53.061.4 pmol/mg prot, measured at
37uC). Binding kinetics of [
3H]almorexant to membrane prepa-
rations from HEK293 cells transiently expressing rHCRTR2 are
shown in Fig. 1C and D and the kinetic parameters in Table 1.
The association binding of [
3H]almorexant to the rHCRTR2 had
a half-maximal binding at 10 min and reached equilibrium within
50 min. The data were fit to a one-phase exponential model with
the association rate constant of 0.07360.015 nM
21min
21. The
dissociation rate for [
3H]almorexant binding to the rHCRTR2
was determined by the addition of an excess amount of almorexant
(5 mM) after equilibrium was reached. The rate of [
3H]almorexant
dissociation from rHCRTR2 membrane was slow; the reversal of
binding was incomplete and did not reach baseline even after 2 h
(Fig. 1D & Table 1).
The potencies of almorexant and of the selective HCRTR1
antagonists SB-334867 [6] and SB-408124 [34] in inhibiting
[
3H]almorexant binding to HEK293-rHCRTR1 and HEK293-
rHCRTR2 cell membranes are given in Table 2. Almorexant was
able to displace [
3H]almorexant binding from rHCRTR1 and
rHCRTR2membraneswithhighaffinity(Table2).Incontrast,SB-
334867 and SB-408124 displaced [
3H]almorexant binding from
rHCRTR1,but not from rHCRTR2,withhigh affinity (Table 2).
Pharmacokinetic Studies
Pharmacokinetic properties of SB-334867, SB-408124,
EMPA and almorexant in rats. The oral bioavailability and
pharmacokinetic properties of almorexant, SB-334867 and SB-
408124 were evaluated in Wistar rats. The mean pharmacokinetic
parameters after single iv or oral (po) bolus administration in rat
Hypocretin Receptor Antagonism and Sleep Promotion
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plasma clearance, high volume of distribution at steady state (Vss)
and low oral bioavailability in rat. In addition, almorexant was
highly bound to plasma proteins (,3.7%, and ,8.7% free fraction
in human and rat plasma, respectively), and its stability measured
for 2 h in human and rat plasma was 90.0% and 95.0%,
respectively. The mean brain/plasma concentration ratio of
almorexant was 0.12 in rat.
SB-334867 exhibited a low systemic plasma clearance, medium
Vss and oral bioavailability in rat. SB-334867 is highly bound to
plasma proteins (1.3%, and 0.8% free fraction in human and rat
plasma, respectively), and its stability measured for 1 h/4 h in
human and rat plasma was 95%/93% and 104%/110%,
respectively. The mean brain/plasma concentration ratio of SB-
334867 (at a dose of 8.8 mg/kg, po) was 0.53 in rat.
SB-408124 had a low systemic plasma clearance, low Vss and
medium oral bioavailability in rat. SB-408124 had very low free
fraction in human and rat (0.3% and ,0.1%, respectively) and its
stability (1 h/4 h) in human and rat plasma was 94%/88% and
101%/107%, respectively. The mean brain/plasma concentration
ratio of SB-408124 (at dose of 18 mg/kg, po) was 0.03 in rat. Such
unfavorable pharmacokinetic properties of SB-408124, most
importantly its extremely low brain penetration, prompted us to
use SB-334867 for further in vivo studies in the rat.
The pharmacokinetic profiles of EMPA have been reported
previously [37].
Figure 1. Binding characteristics of [
3H]almorexant to rHCRTR1 and rHCRTR2 cell membranes. (A,B) Saturation binding curves of
[
3H]almorexant binding to membranes from HEK293 cells transiently transfected with rHCRTR1 (A) or rHCRTR2 (B). Each data point represents the
mean6SEM of three independent experiments performed in triplicate. The data were analyzed by nonlinear regression analysis using GraphPad
Prism 4.0 software and a single-site binding model. (C,D) Time course for the association (C) and dissociation (D)o f[
3H]almorexant binding to
rHCRTR2 membranes.
doi:10.1371/journal.pone.0039131.g001
Table 1. Kinetic parameters for the association and dissociation of [
3H]almorexant in rHCRTR2-HEK293 cell membranes at 37uC.
Compound Association kinetic Dissociation kinetic Apparent
Kon (nM
21min
21)K off (min
21)t 1/2 (min) Kd (nM)
[
3H]almorexant 0.07360.015 0.02160.004 36.365.7 0.3360.9
The Kon (calculated on rate), Koff (observed off rate), t1/2 (half-maximal binding) and Kd (apparent dissociation constant) values are 6 SEM, calculated from three
independent experiments (each performed in quadruplicate) as described under ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0039131.t001
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334867 at the HCRTR1 was confirmed by assessment in
radioligand binding assays in a broad CEREP screen (Paris,
France; www.cerep.fr) (Table S2). Among the 79 receptors tested,
30 were peptide receptors. SB-334867 was inactive (,40% activity
at 10 mM) at all targets tested with the exception of the A2A
(adenosine), A3, MT3 (melatonin), P2Y (purinergic 2Y) and 5HT2C
(serotonin 2C) receptors, where it caused 89%, 63%, 102%, 64%
and 70% displacement of specific binding at 10 mM, respectively.
The selectivity profiles of almorexant [27] and EMPA [37] have
been reported previously.
Effect of Almorexant and SB-334867 on Spontaneous
Locomotor Activity in Rats
The ability of almorexant and SB-334867 to antagonize in vivo
the biological action of endogenous hypocretins was assessed by
measuring spontaneous LMA during the active phase. Almorexant
dose-dependently reduced LMA, although only the 30 mg/kg
dose reached significance when compared to vehicle (Figure 2A;
F=4.28, p,0.05). Similarly, SB-334867 dose-dependently re-
duced spontaneous LMA, with both the 10 and 30 mg/kg doses
being statistically different from vehicle (Figure 2B; vehicle:
60976536; 10 mg/kg: 35096383; 30 mg/kg: 26266341;
F=12.80, p,0.01 and p,0.001, respectively).
The plasma and brain exposure of SB-334867 were measured at
the end of the LMA experiment. When determined 35 min after
ip administration, SB-334867 doses of 3, 10 and 30 mg/kg
produced plasma levels of 220, 718 and 738 ng/mL vs. brain
levels of 48, 171, and 142 ng/mL (ratios: 0.21, 0.23, 0.19,
respectively). These results confirmed the ability of SB-334867 to
enter the rat brain at the doses used in this report.
Rodent EEG Studies
The effects of almorexant, SB-334867 and EMPA administered
in the middle of the dark (active) period were evaluated during the
latter half of the active period and subsequent light (inactive)
period to determine both efficacy for sleep promotion and whether
‘‘hangover’’ or rebound effects occurred. Of these three com-
pounds, only almorexant reduced NR and REM sleep latency
(Figure 3). Almorexant at 30 and 100 mg/kg reduced NR latency
while only the 30 mg/kg concentration decreased latency to REM
sleep. ZOL produced a decrease in NR latency in all three
experiments.
Incontrast,allthreecompoundsincreasedNRsleep(Figure4).SB-
334867at3and30 mg/kgincreasedcumulativeNRforthefirst4and
6 h periods following administration (F=10.808, p,0.0001 and
F=10.752, p,0.0001, respectively). EMPA at 100 mg/kg also
increased cumulative NR for the first 4 and 6 h periods post
administration (F=17.655, p,0.0001 and F=12.816, p,0.0001,
respectively). Almorexant had the strongest effect: both 30 and
100 mg/kg increased cumulative NR for 2, 4 and 6 h following
administration (F=13.010, p,0.0001; F=17.771, p,0.0001; and
F=16.179, p,0.0001, respectively). Cumulative REM also in-
creasedforthefirst2 hfollowingalmorexantat30 mg/kg(F=5.418,
p=0.0023) and for the 6 h period following the 100 mg/kg dose
(Figure4;F=8.535,p,0.0001).ZOLincreasedcumulativeNRand
decreasedcumulativeREMinallthreeexperiments.WhereasZOL
suppressed the REM:NR ratio in all 3 studies, none of the 3 test
compounds did (Table 3). Although ZOL had significant effects on
EEGdeltapowerduringNR,thisparameterwaslittleaffectedbyany
ofthethreetestcompoundscomparedtovehiclecontrol(FigureS2).
There were few effects on sleep/wake amounts during the light
period subsequent to administration of EMPA, SB-334867 or
almorexant (Figure 5). REM was not significantly affected during
this period following any of the three HCRT antagonists. NR
decreased during the third hour of the light period (ZT3) following
SB-334867at10and30 mg/kgwhileNRincreasedduringZT1and
ZT6 following almorexant at 30 mg/kg compared to vehicle. No
significanteffectsonNRwerefoundfollowingEMPAduringthelight
period.
Significant results occurred in measures of sleep-wake consolida-
tion(TablesS3,S4,S5andFiguresS3,S4,S5).Thestrongesteffects
were found following almorexant at 100 mg/kg, which produced
increased numbers of W and NR bouts during ZT19, ZT20, and
ZT22-ZT24 (F=2.069, p=0.0077 and F=2.413, P=0.0015,
respectively). The number of REM bouts was increased by
almorexant at 100 mg/kg during ZT22-ZT24 (F=2.963,
p=0.002). W bout duration was decreased following almorexant at
100 mg/kg during ZT22 compared to vehicle (F=2.320,
p=0.0023).AllthreeconcentrationsofEMPAincreasedthenumber
of W bouts (F=4.243, p=0.0065). SB-334867 increased NR bout
duration during ZT21 following 30 mg/kg and during ZT24
following 3 mg/kg (F=4.574,p,0.0001).
Both LMA and Tcore underwent dose-dependent decreases after
drug treatment (Figure 6). ANOVA revealed condition effects for
both almorexant and EMPA in which LMA was decreased across
the 6 h period following administration of both compounds at
100 mg/kg compared to vehicle (F=7.316, p,0.00015 and
F=7.442, p=0.00018 respectively). No differences in LMA
during the subsequent light period were found. Condition effects
for Tcore were found in all three studies. The high concentrations
tested for all three HCRT receptor antagonists decreased Tcore
across the 6 h period following administration (F=7.629,
p=0.00027 for SB-334867; F=7.442, p=0.00018 for EMPA;
F=7.315, p=0.00036 for almorexant). ZOL administration
resulted in the largest declines in Tcore in all three studies, which
was followed by a sustained rebound increase in Tcore during the
subsequent light period.
Time Course of HCRT Receptor Occupancy (RO) by
Almorexant
To determine the time-course of HCRTR1 and HCRTR2 RO
by almorexant, a single dose of almorexant at the smallest
concentration shown to promote sleep (30 mg/kg, ip; Figure 4)
was administered in the mid-dark phase (ZT18) and rats were
Table 2. Potencies of almorexant, SB-408124 and SB-334867
antagonists in inhibition of [
3H]almorexant binding to the
membrane preparations from HEK293 cells transiently
expressing rHCRTR1 and rHCRTR2.
Compound rHCRTR1 rHCRTR2
[
3H]almorexant (236C) [
3H]almorexant (376C)
Ki (nM) Ki (nM)
almorexant 7.160.7 2.060.0
SB-408124 45.764.1 5370.062200.0
SB-334867 58.462.9 2390.0681.0
[
3H]almorexant was used at a concentration equal to its Kd values of 3.4 nM and
0.5 nM at rHcrtR1 and rHcrtR2, respectively, in these competition binding
experiments. Ki values for [
3H]almorexant binding inhibition by various
antagonists were calculated as described under ‘‘Materials and Methods’’.
Values are 6 SEM of the Ki calculated from three independent experiments,
each performed in duplicate.
doi:10.1371/journal.pone.0039131.t002
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both HCRTR1 and HCRTR2, the NSB was minimal and
represented 6.2% and 3%, respectively, of the average TB signal
measured in control animals. The signal localization was in good
agreement with the distribution of HCRTR1- and HCRTR2-
expressing neurons [42,43], as confirmed by in situ hybridization
on separate sections (data not shown). Figure 7A shows
representative autoradiograms of HCRTR1 binding sites in the
locus coeruleus (LC). This signal localization is in good agreement
with the distribution of Hcrtr1-expressing neurons [42,43], as
confirmed by in situ hybridization (data not shown). The rats
injected with vehicle displayed maximal HCRTR1 radiotracer
binding at all time points (Figure 7A), whereas the animals injected
with almorexant showed reduced binding 2 h after the injection.
Binding of the HCRTR1 radiotracer returned to levels similar to
control 8–12 h post almorexant injection.
Figure 7B shows representative autoradiograms of the
HCRTR2 binding sites examined at 2 different rostro-caudal
levels. At the level of the posterior hypothalamus, signal was
observed in various brain regions, including the tuberomammil-
lary nuclei (TMN), cerebral cortex (CC), retrosplenial cortex (RSC),
and field CA3 of the hippocampus (CA3). The signal attributed to
the TMN was verified by in situ hybridization for histidine
decarboxylase mRNA on separate sections (data not shown). At
the level of the anterior pons, the dorsal raphe nuclei (DRN),
pontine nuclei (Pn) and parabigeminal nuclei (PBG) displayed
specific labeling. This pattern corresponds to that already reported
by Malherbe et al. [37] and was in good agreement with the
distribution of Hcrtr2-expressing neurons previously described
[42,43]. The rats injected with vehicle displayed constant
HCRTR2 binding at all time points. In contrast, the animals that
received almorexant exhibited a very strong reduction of
HCRTR2 radiotracer binding and, 2 h after almorexant injection,
no signal could be detected (Figure 7B). Reduction of TB signal
was still evident for all brain regions 12 h after almorexant
administration.
SB was quantified in the LC for HCRTR1 and in 6 brain areas
(TMN, CC, CA3, RSC, DRN and Pn) for HCRTR2, and the RO by
almorexant was determined for 12 h post-injection (Figure 7C and
Figure S7). HCRTR1 RO reached 50–60% from 30 min to 4 h
post-injection (maximum: 59% after 2 h) and then returned to
basal levels after 6 h. This RO profile paralleled that of
almorexant concentration in the plasma (Figure 7D) and brain
(Figure S6). For both compartments, drug concentration rose
rapidly and reached a peak around 30 min, with plasma levels of
1966.46349.2 ng/mL and brain levels of 565.86112.4 ng/g
(mean brain/plasma concentration ratio: 0.28). The half-maximal
concentrations were achieved between 4 and 6 h.
For HCRTR2, all 6 structures displayed a comparable RO
profile (Figure 7C for DRN and TMN, and Figure S7 for CC, RSC,
Pn and CA3): it was close to 100% within 30 min after dosing,
remained at maximal levels at 2 h and 4 h, and started to slowly
decline between 4 and 6 h. After 12 h, although the brain and
plasma levels of almorexant were strongly reduced (Figure 7C and
Figure S6), HCRTR2 occupancy was still elevated with levels
between 49 and 67%, depending on brain structure (Figure 7C
and Figure S7; TMN: 49.2613.2%; CC: 66.1611.6%;
CA3:58.4611.5%; RSC: 64.6610.7%; DRN: 57.7610.5%; Pn:
67.2613.9%).
Discussion
This study was undertaken to determine whether blockade of
either or both HCRT receptors is more effective in promoting
sleep. Multiple dual HCRTR1/R2 antagonists employing
different molecular scaffolds have been found to have significant
significant sleep-promoting properties [25,26,27,28,29,30,31]
Anatomical localization of HCRTRs suggests that both recep-
tors are involved in the promotion of wakefulness [39,43]. High
levels of HCRTR1 are found in LC while only HCRTR2 is
abundant in the TMN. Both receptors are expressed at
moderately high levels in the dorsal and medial raphe and in
the cholinergic regions of the basal forebrain. In the laterodorsal
tegmentum and the pedunculopontine nucleus (brain stem
cholinergic regions), the HCRTR1 is predominant. However,
some recent reports support the hypothesis that only blockade
of the HCRTR2 underlies the hypnotic actions of HCRTR
antagonism [30,31]. Further, one study suggests that antagonism
Figure 2. Effects of almorexant and SB-334867 on spontaneous locomotor activity of rats during the active phase. Both almorexant
(A) and SB-334867 (B) reduced locomotor activity compared to vehicle (Veh) when administered 3 h after the onset of the dark period. Horizontal
locomotor activity was recorded for a period of 30 min. Numbers on the X-axes represent intraperitoneal doses in mg/kg.***p,0.001, **p,0.01,
*p,0.05 vs. Veh (one-way ANOVA followed by Dunnett’s analysis). All data are mean6SEM (n=8 per group).
doi:10.1371/journal.pone.0039131.g002
Hypocretin Receptor Antagonism and Sleep Promotion
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e39131of HCRTR1 attenuates the hypnotic actions of HCRTR2
blockade [32]. Therefore, to help clarify the hypnotic effects of
HCRTR blockade, we characterized the pharmacological and
pharmacokinetic properties of selective and dual HCRTR
antagonists in rat before evaluating their relative efficacy on
sleep and wakefulness.
Pharmacokinetic Considerations
The affinities of almorexant, SB-408124 and SB-334867 at
the rat HCRTR1 and HCRTR2 receptors are very similar to
those reported for human HCRT receptors (for almorexant, Ki
values of 4.7 nM and 0.9 nM at hHCRTR1 and hHCRTR2,
37uC, respectively [42]; for SB-334867, Ki value of 38.7 nM at
rHCRTR1 [34]; for SB-408124, Ki value of 26.9 nM at
rHCRTR1 [34]). Almorexant had high affinity for both
HCRTRs and displayed a slow rate of dissociation from
rHCRTR2 membranes in vitro, which translated into a long-
lasting occupancy of the HCRTR2 in vivo. This property likely
underlies some of the pharmacological effects described here.
Among the three antagonists tested, almorexant had the highest
systemic plasma clearance, highest Vss but lowest oral
bioavailability; both SB-334867 and SB-408124 had low
clearances and medium to low bioavailability. Importantly,
SB-408124 had a very low free fraction and was found to
penetrate the brain poorly, especially when compared to the
other compounds. This prompted us to use SB-334867 for
evaluating the effects of selective HCRTR1 blockade on sleep.
Effects of Selective HCRTR1 and HCRTR2 Antagonists on
Sleep/wake
Selective blockade of HCRTR2 clearly results in sleep
promotion. The HCRTR2 antagonist JNJ-10397049 reduced
NR latency during both the light and dark phases, increased NR
duration in the light phase, and increased both NR and REM
duration during the dark phase [30,31]. Here, although EMPA
had no effect on either NR or REM latency when administered in
the mid-dark phase, it increased cumulative NR for the first 4 and
6 h. Conversely, icv infusion of an HCRTR2 agonist, [Ala
11]or-
exin-B, during the light period dose-dependently increased wake
duration and decreased the amounts of both NR and REM sleep
[44]. The effects of HCRT1 (orexin-A) on wakefulness and
NREM sleep were reduced more in OX2R
2/2 mice than in
OX1R
2/2 mice, implying that HCRTR2 has a greater influence
than HCRTR1 on these parameters, at least in mice [45].
The selective HCRTR1 antagonist SB-334867 dose-depen-
dently reduced LMA and, at 3 and 30 mg/kg i.p., increased
cumulative NR for the first 4 and 6 h. These results differ from
those of Dugovic et al. [32] who reported that selective blockade of
HCRTR1 using SB-408124 had no effect on sleep, although it
reduced LMA. However, the time of drug administration differed
between these studies (middle vs. start of the active phase). By the
middle of the active phase, both endogenous HCRT tone [46,47]
and sleep pressure are increased, so HCRTR antagonists are more
likely to be effective at this time of day than at dark onset.
A previous study showed that SB-334867 blocked HCRT1-
induced effects on REM sleep but did not alter any sleep
parameters when administered alone [36]. However, only the first
hour after treatment was examined whereas, here, effects of SB-
334867 on sleep were only apparent after 2 h. Importantly, we
showed that SB-408124 exhibits poor pharmacokinetic properties,
with notably low free fraction and little brain penetration, which
likely limits its in vivo efficacy. The brain-to-plasma ratio for SB-
408124 is 0.03, which is in the range of blood contamination levels
obtained with the residual blood carried over in the brain
homogenate (in the absence of compound in the brain). Although
Dugovic et al. [32] did not specifically report brain-to-plasma
ratios, they did report both brain and plasma concentrations
following administration of SB-408124 at 30 mg/kg. Using these
numbers, a brain-to-plasma ratio for SB-408124 is calculated to be
0.012 (using Cmax values given in text: brain-to-plasma ra-
tio=1.09/84.29=0.012), which is in good agreement with our
findings. This observation most likely explains why Dugovic et al.
[32] did not detect effect on sleep. There are numerous examples
of compounds lacking central efficacy due to insufficient brain
exposure. For example, the reduced ability of second-generation
H1 anti-histaminic drugs to cross the blood-brain barrier (BBB) as
compared to the first generation of drugs, prevents them from
causing centrally-mediated side effects such as sedation [48,49,50].
Similarly, the antidiarrheal medication loperamide is a potent
agonist of the m opiate receptor that is devoid of opioid central
effects at usual doses in patients [51]. This directly results from the
Figure 3. Latency to the onset of NR and REM sleep following
administration of SB-334867. (A), EMPA (B), and almorexant (C) as
compared to zolpidem (ZOL). *=significantly different from vehicle
(p,0.05); +=significantly different from ZOL (p,0.05) (One-way
repeated measures ANOVA followed by paired two-tail t tests; n=8
per group). Data represent the mean6SEM.
doi:10.1371/journal.pone.0039131.g003
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at the BBB [51]. Administration of the drug to P-gp-deficient mice
or co-administration with a P-gp blocker both increase brain levels
and trigger central effects typically observed with brain penetrant
opioids, such as analgesia [52,53] or respiratory depression [54].
Our observation made with SB-408124 underscores that verifica-
tion of brain penetration is a prerequisite for the conception and
use of centrally-acting drugs [55,56].
On the other hand, it is difficult to reconcile the poor brain
penetration of SB-408124, both documented here and also evident
in the study of Dugovic et al. (estimation: 0.012), with some
indications of central localization following subcutaneous admin-
istration of 30 mg/kg, i.e. the 90% HCRTR1 occupancy observed
in the tenia tecta and the SB-408124-mediated elevation of
extracellular dopamine levels in the prefrontal cortex [32]. A
heterogeneous distribution of the drug is unlikely, and further
experiments will be necessary to delineate more precisely the free
concentration of the compound, such as microdialysis studies and
measures of binding to brain tissue homogenates.
Figure 4. Cumulative time in NR and REM sleep over the first 2, 4 and 6 h following drug administration. (A–C) Cumulative time spent
in NR sleep following SB-334867 (A), EMPA (B) and almorexant (C) compared to zolpidem (ZOL). (A’–C’) Cumulative time spent in REM sleep for the
same drug treatments. (One-way repeated measures ANOVA followed by paired two-tail t tests; n=8 per group). Data represent the mean6SEM. *,
significantly different from vehicle; +, significantly different from ZOL.
doi:10.1371/journal.pone.0039131.g004
Table 3. REM:NR ratios for the 6 h period following the
administration of SB-334867, EMPA and almorexant.
Vehicle SB-334867 SB-334867 SB-334867 ZOL
3 mg/kg 10 mg/kg 30 mg/kg 7.5 mg/kg
0.2260.039 0.2160.016
+ 0.2260.023
+ 0.2360.016
+ 0.1260.009*
Vehicle EMPA EMPA EMPA ZOL
10 mg/kg 30 mg/kg 100 mg/kg 10 mg/kg
0.1860.018 0.1660.019
+ 0.2160.032
+ 0.1860.027
+ 0.0860.008*
vehicle Almorexant Almorexant Almorexant ZOL
10 mg/kg 30 mg/kg 100 mg/kg 10 mg/kg
0.1860.020 0.1960.026
+ 0.2060.022
+ 0.2160.021
+ 0.0560.013*
*=significantly different from vehicle (p,0.05),
+=significantly different from
ZOL (p,0.05).
doi:10.1371/journal.pone.0039131.t003
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Medications
Dual HCRTR1/R2 antagonists are now well-established to
induce sleep. In rats, almorexant administered po at the beginning
of the dark phase promoted both NR and REM sleep and, at a
higher dose, reduced NR and REM latency [27]. The effects on
sleep duration but not sleep latency were confirmed when
almorexant was administered sc [32]. Here, we report that
almorexant given ip at the mid-dark phase also increases sleep
duration. However, in contrast to Dugovic et al., we found that
almorexant at 30 and 100 mg/kg reduced NR latency and the
30 mg/kg dose also decreased REM latency. These differences
likely reflect the greater sensitivity of the sleep/wake bioassay
when injections occur in the mid-dark period after a sleep debt has
accumulated. Recently, other dual HCRTR1/R2 antagonists
have also been reported to reduce active wake and increase both
NR or delta sleep and REM sleep when administered near the
mid-dark phase [25,26,27,28,29,30,31,57]. Thus, multiple
HCRTR1/R2 antagonists seem to be effective in inducing sleep.
Our results indicate some promising aspects of HCRT
antagonists as hypnotic agents. First, in contrast to current
hypnotics such as zolpidem which increase NR and suppress
REM sleep, none of the three HCRTR antagonists affected the
REM:NR ratio, indicating that both REM and NR increased
proportionally. Second, in comparison to zolpidem, HCRTR
antagonists only triggered a limited, physiological reduction of
body temperature. Lastly, no excess wakefulness was observed
during the subsequent light period. A proportional increase of
Figure 5. Hourly distribution of W, NR and REM sleep. W, NR and REM sleep for 6 h prior to and 18 h after administration of SB-334867 (A),
EMPA (B), and almorexant (C) as compared to zolpidem (ZOL) and vehicle. Shaded area represents the dark phase; vertical dotted line in each panel
indicates the time of injection. (A) Hourly amounts of wakefulness following SB 334867. (A’) Hourly amounts of NR sleep following SB 334867. (A’’)
Hourly amounts of REM sleep following SB 334867. (B) Hourly amounts of wakefulness following EMPA. (B’) Hourly amounts of NR sleep following
EMPA. (B’’) Hourly amounts of REM sleep following EMPA. (C) Hourly amounts of wakefulness following almorexant. (C’) Hourly amounts of NR sleep
following almorexant. (C’’) Hourly amounts of REM sleep following almorexant. Data represent the mean6SEM (n=8 rats per group). *, p,0.05. For
detailed statistical results, see Text S1.
doi:10.1371/journal.pone.0039131.g005
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change in core temperature are desirable properties of substances
that induce ‘‘physiological’’ sleep.
On the other hand, the mechanism by which these HCRTR
antagonists increased sleep duration suggests disruption of normal
sleep/wake architecture. SB-334867 increased NR through a
Figure 6. Average hourly LMA and relative Tcore. LMA and relative Tcore for 6 h prior to and 18 h after administration of SB-
334867 (A), EMPA (B), and almorexant (C) as compared to zolpidem (ZOL) and vehicle. Shaded area represents the dark phase;
vertical dotted line in each panel indicates the time of injection. (A) Average hourly LMA following SB-334867. (A’) The average hourly Tcore
following SB-334867. (B) The average hourly LMA following EMPA. (B’) The average hourly Tcore following EMPA. (C) The average hourly LMA
following almorexant. (C’) The average hourly Tcore following almorexant. Data represent the mean6SEM (n=8 rats per group). *, p,0.05. For
detailed statistical results see Text S1.
doi:10.1371/journal.pone.0039131.g006
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NR bouts that, although not significant for any particular hour,
cumulatively summated into an overall significant NR increase at
4 and 6 h. For EMPA, a greater number of NR bouts underlie the
overall increase in NR at the highest dose. For almorexant, NR
augmentation resulted from an increased number of NR bouts
without a change in bout duration, confirming previous results
[32]. The increase in NR, however, was also associated with
greater numbers of both W and REM bouts, particularly at the
highest dose examined. Thus, although almorexant produces an
overall increase in NR sleep that is greater than the other HCRTR
antagonists, this is achieved through a fragmented sleep architec-
ture. In this regard, almorexant-treated rats appear somewhat
similar to orexin null mutant [4] or orexin/ataxin-3 [12] mice which
have disrupted sleep architecture (although these strains also
exhibit cataplexy). However, the fragmentation of sleep architec-
ture induced by dual HCRTR antagonists is consistent with the
concept that the HCRT system stabilizes arousal states and
minimizes the number of transitions between states [58]. Since
drugs were administered to healthy animals during their active
period, a more fragmented sleep architecture would be predicted.
Rather than driving sleep per se, HCRTR antagonism seems to
create a permissive neural environment for sleep to occur. Since
the drive for sleep was low at the time of administration, more
frequent sleep bouts without increases in bout durations could be
expected.
Figure 7. Time-course of HCRT1R and HCRT2R occupancies by almorexant. (A,B) Representative autoradiograms showing [3H]SB-
674042 (5 nM) binding to HCRTR1 (A) and [3H]EMPA (1 nM) binding to HCRTR2 (B) in rat coronal brain sections. For both receptors, total
binding (TB) was maximal in control animals (not injected) sampled at time 0 (t0). For HCRTR1 (A), a clear signal was evident in the locus
coeruleus (LC), which could be displaced by co-incubation with an excess of cold SB-674042 (10 mM) (non-specific binding, NSB). In contrast to
vehicle administration (Veh, 2 h), almorexant (30 mg/kg injected intraperitoneally at ZT18) attenuated such specific signal after 2 h (Almo, 2 h),
but not after 12 h (Almo, 12 h). For HCRTR2 (B), signal was observed in various brain regions, including the tuberomammillary nuclei (TMN),
cerebral cortex (CC), field CA3 of the hippocampus (CA3), retrosplenial cortex (RSC), dorsal raphe nuclei (DRN), pontine nuclei (Pn) and
parabigeminal nuclei (PBG). [3H]EMPA could be displaced by co-incubation with an excess of Cp5 (10 mM) (NSB). HCRTR2 binding became
minimal 2 h after almorexant (Almo, 2 h), but not after Vehicle (Veh+2h ), administration. After 12 h (Almo, 12 h), HCRTR2 binding was
intermediate. Scale bars, 2 mm. (C) Time course of HCRTR1 and HCRTR2 occupancies by almorexant. Receptor occupancy was calculated by
measuring the specific binding at various time points in the LC for HCRTR1, and in the TMN and DRN for HCRTR2. *, p,0.001 versus time 0; (#),
p,0.05 (TMN only), #, p,0.05 (TMN) or p,0.01 (DRN), vs. time 30 min (one-way ANOVA followed by Dunnett’s analysis). (D) Almorexant
plasma concentrations. Data represent the mean6SEM (n=5 rats per group).
doi:10.1371/journal.pone.0039131.g007
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One concern regarding the development of HCRTR antago-
nists is the possibility of inducing cataplexy as occurs in HcrtR2
mutant dogs [3] or HcrtR2 null mutant mice [59]. In the present
study, we saw no evidence of cataplexy produced by any of the
three compounds, even at the highest dose tested. However,
almorexant significantly increased REM bout duration during the
first hour after treatment and the highest dose – which presumably
resulted in the most complete HCRTR blockade – produced 2 to
3 fold as many REM bouts during the latter half of the dark period
when compared to vehicle. These observations indicate that
HCRTR antagonism facilitates REM sleep occurrence, as noted
by others [59].
Relationship between HCRTR Occupancy and Sleep
Whereas 30 mg/kg ip almorexant resulted in approximately
50% HCRTR1 occupancy, HCRTR2 occupancy was nearly
complete in brain regions important for sleep/wake control.
Moreover, while HCRTR1 occupancy declined after 4 h,
HCRTR2 occupancy remained high even 12 h after treatment.
While our results for HCRTR2 are consistent with a previous
report, those for HCRTR1 differ [32]. A primary difference
between these studies is the brain location used for determination
of HCRTR1 occupancy: whereas Dugovic et al. used the tenia tecta,
we measured HCRTR1 occupancy in the LC, an area implicated
in sleep/wake control.
Figure 8 correlates RO with the net amount of sleep induced by
almorexant at 30 mg/kg compared to vehicle. Since HCRTR2
occupancy is virtually 100% following this dose of almorexant
while HCRTR1 occupancy is ,50%, it is likely that the stronger
sleep-promoting effects observed at 100 mg/kg are due to greater
HCRTR1 blockade. Figure 8 demonstrates that the sleep-
promoting effects of almorexant do not simply mirror the RO
data. The greatest amount of sleep occurred in the first hour after
almorexant administration when occupancy of HCRTRs was
maximal. Surprisingly, despite elevated occupancy of HCRTRs in
subsequent hours, the hypnotic effect dissipated, suggesting that
other arousal-promoting systems can overcome HCRTR blockade
and produce wakefulness. In contrast, near the end of the dark
phase when sleep pressure is elevated, partial HCRTR blockade
was sufficient to produce sleep. These data highlight the
contrasting sleep-promoting mechanisms between HCRTR an-
tagonists and other hypnotic medications such as zolpidem.
Whereas the latter compounds trigger long-lasting sleep and affect
sleep intensity (sleep-inducing effect), HCRTR antagonists seem to
merely antagonize wakefulness, generating conditions that allow
sleep to occur (sleep permissive action).
Conclusion
Our results support the hypothesis that dual HCRTR1/R2
blockade is more effective in promoting sleep than selective
blockade of either HCRTR alone. A similar conclusion was
reached in a recent study of HCRT receptor knockout mice [45].
Although both HCRTR1 (SB-334867) and HCRTR2 (EMPA)
antagonists produced somnogenic effects, neither promoted sleep
to the levels of the dual HCRTR antagonist almorexant.
Furthermore, since the lowest doses of almorexant that were
sleep-promoting (30 mg/kg) bind virtually 100% of the
HCRTR2s while only 50% of the HCRTR1s are occupied at
that dose, the stronger sleep-promoting effects of higher doses are
likely due to additional blockade of HCRTR1. These data support
the notion that HCRTR antagonists are a promising avenue for
sleep/wake therapeutics, with the qualifications stated above.
However, given the involvement of the HCRT system in many
physiological functions [9,60] including respiratory control
[61,62,63,64], careful screening for side effects of HCRTR
antagonists will be needed.
Supporting Information
Figure S1 Chemical structures of the compounds used
in this study. Receptor selectivity is indicated into parentheses.
All compounds except zolpidem are selective HCRTR antago-
nists. Zolpidem is a gama-aminobutyric acid (GABA) A-receptor
agonist.
(TIF)
Figure S2 Hourly delta power normalized to the 24 h
average vehicle control. A: 3 concentrations of SB-334867 vs.
ZOL and vehicle. ANOVA is significant for treatment by time
only (F=3.80, p,0.0001). For treatment by time: ZT19: SB-
334867 at 3 mg/kg . vehicle; ZOL .334867 at 3 and 10 mg/kg
and vehicle. ZT24: 334867 at 3 and 10 mg/kg . ZOL; Vehicle
.334867 at 10 and 30 mg/kg and ZOL B: 3 concentrations of
EMPA vs. ZOL and vehicle. ANOVA is significant for treatment
(see legend, F=13.47, p,0.0001) and for treatment by time
(F=11.86, p,0.0001). For treatment by time: ZT19: ZOL . all
other conditions. ZT20: ZOL . all other conditions. ZT21:
EMPA at 30 mg/kg . vehicle; ZOL . EMPA at 100 mg/kg and
vehicle. ZT22: EMPA at 30 mg/kg . vehicle. ZT23: EMPA at
10 mg/kg . ZOL. C: 3 concentrations of almorexant vs. ZOL
and vehicle. ANOVA is significant for treatment by time only
(F=2.63, p=0.0005). For treatment by time: ZT20: Vehicle .
almorexant at 100 mg/kg. ZT23: Almorexant at 10 mg/kg .
vehicle. ZT24: Vehicle . almorexant at 100 mg/kg.
(TIF)
Figure S3 Hourly distribution of Wake Bout Duration
and the Number of Wake Bouts. Wake Bout Duration (left)
and Number of Wake Bouts (right) for 6 h prior to and 18 h after
administration of SB-334867 (A), EMPA (B), and almorexant (C)
Figure 8. Net effect of almorexant on the percentage of sleep
compared to HCRTR1 and HCRTR2 occupancies. The percentage
of total sleep (%NR + %REM) in the vehicle-injected animals was
subtracted from that of almorexant-treated rats (30 mg/kg) and was
plotted over time. HCRTR1 occupancy in the locus coeruleus (LC) and
HCRTR2 occupancy in the tuberomammillary nuclei (TMN) are shown in
parallel. Injection occurred at ZT18. Gray area, dark phase; White area,
light phase.
doi:10.1371/journal.pone.0039131.g008
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phase; vertical dotted line shows the first h following injection. A:
The Wake Bout Duration for 3 concentrations of SB 334867 vs.
ZOL and vehicle. No significant differences were found. A’: The
Wake Bout Number for 3 concentrations of SB 334867 vs. ZOL
and vehicle. ANOVA for ZT1-ZT6 is significant for treatment by
time (F=1.82, p=0.02341). For treatment by time: ZT2: SB
334867 at 10 mg/kg and vehicle , ZOL vehicle , SB 334867 at
30 mg/kg ZT4: SB 334867 at 30 mg/kg and ZOL , vehicle B:
The Wake Bout Duration for 3 concentrations of EMPA vs. ZOL
and vehicle. No ANOVA’s were significant. B’: The Wake Bout
Number for 3 concentrations of EMPA vs. ZOL and vehicle.
ANOVA for ZT19-ZT24 is significant for treatment (F=3.65,
p=0.01350). ANOVA for ZT7-ZT12 is significant for treatment
(F=4.24, p=0.00647) For treatment by time: ZT19: vehicle ,
ZOL ZT20: vehicle , EMPA at 30 mg/kg ZT22: vehicle ,
ZOL ZT24: vehicle , EMPA at 10, 30 and 100 mg/kg ZT7:
EMPA at 10 mg/kg , ZOL ZT11: vehicle , ZOL C: The Wake
Bout Duration for 3 concentrations of Almorexant vs. ZOL and
vehicle. ANOVA for ZT19-ZT24 is significant for treatment
(F=4.01, p=0.01077) and for treatment by time (F=2.32,
p=0.00234). For treatment by time: ZT20: Almorexant at
100 mg/kg , ZOL ZT21: Almorexant at 30 and 100 mg/kg
, ZOL ZT22: Almorexant at 100 mg/kg , ZOL and vehicle
C’: The Wake Bout Number for 3 concentrations of Almorexant
vs. ZOL and vehicle. ANOVA for ZT19-ZT24 is significant for
treatment (F=8.82, p=0.00001) and for treatment by time
(F=2.07, p=0.00769). ANOVA for ZT7-ZT12 is significant for
treatment (F=3.39, p=0.02208). For treatment by time: ZT19:
vehicle , Almorexant at 30 and 100 mg/kg ZT20: ZOL ,
Almorexant at 10, 30 and 100 mg/kg ZT21: ZOL , Almorexant
at 30 and 100 mg/kg ZT22:ZOL and vehicle , Almorexant at
100 mg/kg ZT23: vehicle , Almorexant at 100 mg/kg ZT24:
vehicle , Almorexant at 100 mg/kg ZT9: Almorexant at 10 and
30 mg.kg , vehicle.
(TIF)
Figure S4 Hourly distribution of NR Bout Duration and
Number of NR Bouts. NR Bout Duration (left) and Number of
NR Bouts (right) for 6 h prior to and 18 h after administration of
SB-334867 (A), EMPA (B), and almorexant (C) as compared to
zolpidem (ZOL). Shaded area represents the dark phase; vertical
dotted line shows the first h following injection. A: The NR Bout
Duration for 3 concentrations of SB 334867 vs. ZOL and vehicle.
ANOVA for ZT19-ZT24 is significant for treatment (F=12.46,
p,0.00001) and for treatment by time (F=4.57, p,0.00001).
ANOVA for ZT1-ZT6 is significant for treatment (F=4.70,
p=0.00498) and for treatment by time (F=3.16, p=0.00004).
For treatment by time: ZT19: SB 334867 at 3 mg/kg and vehicle
, ZOL ZT20: all other conditions , ZOL ZT21: vehicle , SB
334867 at 30 mg/kg and ZOL ZT24: vehicle , SB 334867 at
3 mg/kg ZT1: ZOL , SB 334867 at 3 and 10 mg/kg and vehicle
SB 334867 at 3 mg/kg , vehicle ZT3: SB 334867 at 30 mg/kg
and ZOL , vehicle A’: The NR Bout Number for 3
concentrations of SB 334867 vs. ZOL and vehicle. ANOVA for
ZT1-ZT6 is significant for treatment by time (F=1.81,
p=0.02532). For treatment by time: ZT1: vehicle , SB 334867
at 3 and 30 mg/kg and ZOL ZT4: SB 334867 at 3 mg/kg ,
vehicle B: The NR Bout Duration for 3 concentrations of EMPA
vs. ZOL and vehicle. ANOVA for ZT19-ZT24 is significant for
treatment (F=13.46, p,0.00001) and for treatment by time
(F=5.34, p,0.00001). ANOVA for ZT1-ZT6 is significant for
treatment (F=7.99, p=0.00010). ANOVA for ZT7-ZT12 is
significant for treatment (F=3.03, p=0.02981). For treatment by
time: ZT19: all other conditions , ZOL ZT20: all other
conditions , ZOL ZT23: ZOL , EMPA at 10 mg/kg ZT24:
ZOL , EMPA at 30 mg/kg ZT2: ZOL , EMPA at 30 mg/kg
ZT3: ZOL , EMPA at 10 and 100 mg/kg and vehicle ZT5:
ZOL , EMPA at 10 and 100 mg/kg and vehicle EMPA at 30
and 100 mg/kg , vehicle ZT6: ZOL , EMPA at 10 mg/kg and
vehicle EMPA at 100 mg/kg , vehicle B’: The NR Bout Number
for 3 concentrations of EMPA vs. ZOL and vehicle. No ANOVA’s
were significant. C: The NR Bout Duration for 3 concentrations
of Almorexant vs. ZOL and vehicle. ANOVA for ZT19-ZT24 is
significant for treatment (F=16.44, p,0.00001) and for treatment
by time (F=5.34, p,0.00001). ANOVA for ZT1-ZT6 is
significant for treatment (F=4.83, p=0.00433) and for treatment
by time (F=2.24, p=0.00341). For treatment by time: ZT19: all
other conditions , ZOL vehicle , Almorexant at 100 mg/kg
ZT20: all other conditions , ZOL ZT21: all other conditions ,
ZOL ZT22: Almorexant at 10 and 30 mg/kg , ZOL ZT2: ZOL
, Almorexant at 10 and 30 mg/kg and vehicle Almorexant at
100 mg/kg , vehicle ZT3: ZOL , Almorexant at 10 mg/kg
ZT4: ZOL , Almorexant at 10 mg/kg ZT5: ZOL ,
Almorexant at 10 mg/kg ZT6: ZOL , Almorexant at 30 mg/
kg C’: The NR Bout Number for 3 concentrations of Almorexant
vs. ZOL and vehicle. ANOVA for ZT19-ZT24 is significant for
treatment (F=12.58, p,0.00001) and for treatment by time
(F=2.41, p=0.00149). ANOVA for ZT1-ZT6 is significant for
treatment (F=4.18, p=0.00890). For treatment by time: ZT19:
vehicle , Almorexant at 30 and 100 mg/kg ZT20: ZOL ,
Almorexant at 10, 30 and 100 mg/kg vehicle , Almorexant at
100 mg/kg ZT21: ZOL , Almorexant at 10, 30 and 100 mg/kg
ZT22: ZOL and vehicle , Almorexant at 100 mg/kg ZT23:
vehicle , Almorexant at 100 mg.kg ZT24: vehicle , Almorexant
at 100 mg.kg ZT1: vehicle , ZOL.
(TIF)
Figure S5 Hourly distribution of REM Sleep Bout
Duration and the Number of REM Sleep Bouts. REM
Sleep Bout Duration (left) and the Number of REM Sleep Bouts
(right) for 6 h prior to and 18 h after administration of SB-334867
(A), EMPA (B), and almorexant (C) as compared to zolpidem
(ZOL). Shaded area represents the dark phase; vertical dotted line
shows the first h following injection. A: The REM Bout Duration
for 3 concentrations of SB 334867 vs. ZOL and vehicle. ANOVA
for ZT19-ZT24 is significant for treatment (F=4.40, p=0.00692)
and treatment by time (F=2.16, p=0.00500). For treatment by
time: ZT19: ZOL , SB 334867 at 3 mg/kg ZT20: ZOL , all
other conditions ZT23: vehicle , all other conditions ZT24: SB
334867 at 10 mg/kg , ZOL vehicle , SB 334867 at 3 mg/kg A’:
The REM Bout Number for 3 concentrations of SB 334867 vs.
ZOL and vehicle. ANOVA for ZT19-ZT24 is significant for
treatment by time only (F=4.49, p=0.00625). For treatment by
time: ZT20: ZOL , all other conditions ZT24: vehicle , SB
334867 at 30 mg/kg B: The REM Bout Duration for 3
concentrations of EMPA vs. ZOL and vehicle. ANOVA for
ZT19-ZT24 is significant for treatment by time (F=1.71,
p=0.03515). ANOVA for ZT1-ZT6 is significant for treatment
(F=4.88, p=0.00015) and for treatment by time (F=2.81,
p=0.00015). For treatment by time: ZT21: ZOL , EMPA at
100 mg/kg ZT24: EMPA at 100 mg/kg , vehicle ZT1: EMPA
at 100 mg/kg , ZOL all other conditions , vehicle ZT4: EMPA
at 10 and 30 mg/kg , vehicle ZT5: ZOL , EMPA at 10 mg/kg
B’: The REM Bout Number for 3 concentrations of EMPA vs.
ZOL and vehicle. ANOVA for ZT19-ZT24 is significant for
treatment (F=3.99, p=0.00888) and for treatment by time
(F=1.96, p=0.01112). For treatment by time: ZT20: ZOL , all
other conditions ZT22: vehicle , ZOL ZT23: ZOL , vehicle C:
The REM Bout Duration for 3 concentrations of Almorexant vs.
Hypocretin Receptor Antagonism and Sleep Promotion
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treatment by time (F=6.91, p,0.00001). ANOVA for ZT1-ZT6
is significant for treatment (F=4.45, p=0.00657). For treatment
by time: ZT19: ZOL and vehicle , Almorexant at 10, 30 and
100 mg/kg ZT20: all other conditions , ZOL ZT24:ZOL ,
Almorexant at 10 and 100 mg/kg and vehicle Almorexant at
30 mg/kg , vehicle C’: The REM Bout Number for 3
concentrations of Almorexant vs. ZOL and vehicle. ANOVA for
ZT19-ZT24 is significant for treatment (F=9.29, p=0.00007) and
for treatment by time (F=2.96, p=0.00010). For treatment by
time: ZT19: ZOL and vehicle , Almorexant at 30 mg/kg ZT20:
ZOL , Almorexant at 10 and 30 mg/kg and vehicle ZT21: ZOL
, all other conditions ZT22: ZOL and vehicle , Almorexant at
100 mg/kg ZT23: vehicle , Almorexant at 100 mg/kg ZT24:
ZOL and vehicle , Almorexant at 100 mg/kg.
(TIF)
Figure S6 Brainconcentrationofalmorexant.Timecourse
of almorexant concentration in the brain of rats injected intraper-
itoneally with 30 mg/kg at the mid-dark phase (same animals as in
Figures 7).Data are the mean6SEM(n=5 rats per group).
(PDF)
Figure S7 HCRTR2 occupancy in the cerebral cortex,
retrosplenial cortex, pontine nuclei, and hippocampus.
Data are the mean6SEM (n=5 rats per group). *, p,0.001 vs.
time 0; ##, p,0.01, #, p,0.05 vs. time 30 min (one-way
ANOVA followed by Dunnett’s analysis). Almorexant plasma
concentrations (data from Figure 7) are shown for comparison.
(TIF)
Materials and Methods S1 Expanded materials and
methods for both in vitro and in vivo experiments as
referenced in the text.
(DOCX)
Text S1 Expanded legends for Figures 5 and 6 that
include detailed statistical results.
(DOCX)
Table S1 Pharmacokinetic assessment of almorexant,
SB-334867 and SB-408124 after i.v. and p.o. administra-
tion to Wistar rat.
(DOCX)
Table S2 CEREP selectivity screen in the broad radio-
ligand binding assays were undertaken to determine the
pharmacological activity of SB-334867.
(DOCX)
Table S3 Measures of state consolidation for 6 h
following the administration of SB-334867.
(DOCX)
Table S4 Measures of state consolidation for 6 h
following the administration of EMPA.
(DOCX)
Table S5 Measures of state consolidation for 6 h
following the administration of almorexant.
(DOCX)
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